Sera PrognosticsSERA
SERA
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
133% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 12
21% more funds holding
Funds holding: 61 [Q3] → 74 (+13) [Q4]
0% less capital invested
Capital invested by funds: $147M [Q3] → $147M (-$11.9K) [Q4]
3.09% less ownership
Funds ownership: 58.26% [Q3] → 55.18% (-3.09%) [Q4]
35% less call options, than puts
Call options by funds: $235K | Put options by funds: $361K
Research analyst outlook
We haven’t received any recent analyst ratings for SERA.
Financial journalist opinion
Based on 5 articles about SERA published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript
Sera Prognostics Inc (NASDAQ:SERA ) Q4 2024 Earnings Conference Call March 19, 2025 5:00 PM ET Company Participants Peter DeNardo - IR, CapComm Partners Evguenia Lindgardt - President, CEO & Director Austin Aerts - CFO Conference Call Participants Dan Brennan - TD Cowen Margarate Boeye - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Fourth Quarter Fiscal Year 2024 Results. At this time, all participants are in listen-only mode.
Negative
Zacks Investment Research
1 week ago
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.25 per share a year ago.
Neutral
PRNewsWire
1 week ago
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN
SALT LAKE CITY , March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience.
Neutral
PRNewsWire
1 week ago
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS
SALT LAKE CITY , March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study.
Neutral
PRNewsWire
3 weeks ago
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025
SALT LAKE CITY , March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.
Neutral
PRNewsWire
1 month ago
Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference
SALT LAKE CITY , Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m.
Neutral
PRNewsWire
1 month ago
Sera Prognostics Announces Pricing of $50 Million Public Offering
SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its Class A common stock at a public offering price of $3.9999 per pre-funded warrant, which equals the public offering price per share of the Class A common stock less the $0.0001 per share exercise price of each pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sera, are expected to be approximately $50 million.
Neutral
PRNewsWire
1 month ago
Sera Prognostics Announces Proposed Public Offering
SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock. In addition, Sera intends to grant the underwriters a 30-day option to purchase shares of Class A common stock in an amount up to an additional 15% of the total amount of shares of Class A common stock and shares of Class A common stock underlying pre-funded warrants sold in the public offering on the same terms and conditions.
Neutral
PRNewsWire
2 months ago
Sera Prognostics to Host Virtual R&D Day on January 31
Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY , Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m.
Neutral
PRNewsWire
2 months ago
Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY , Jan. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco.
Charts implemented using Lightweight Charts™